Published: 2016-12-24

Compare Brimonidine 0.2% versus Latanoprost 0.005% (Xalatan) in preventing intraocular pressure after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Ardabil city

Habib Ojaghi, Rahim Masoumi, Solmaz Eskandar-Sani


Background: The transient increase of intraocular pressure (IOP) following neodymium YAG laser capsulotomy can occur in a significant number of patients, which requires prophylactic treatment with IOP reducing drugs, and in some patients, postoperative IOP monitoring. This study was performed to compare the efficacy of brimonidine 0.2% versus latanoprost0.005% (Xalatan) in preventing the IOP elevation after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Alavi Hospital.

Methods: This study was a randomized, double-blind clinical trial that included 100 patients who had developed posterior capsule opacification (PCO) as a result of previous cataract surgery and were candidate for undergoing YAG laser posterior capsulotomy. The patients were randomly divided into two groups of 50 patients. One group received brimonidine 0.2% one hour before surgery, and the other group received Xalatan 0.005% in the night before laser surgery. In both groups the patients' IOP was measured in baseline, 1, 2, 3, 24 hours, 3 days and one week after surgery. The gathered data were analyzed using statistical methods in SPSS.16.

Results: The mean IOP, 1, 2, 3, and 24 hours, 3 days, and one week after surgery didn't show any significant difference between two groups. IOP one hour before surgery changed significantly compared to one hour after surgery and a statistically significant relationship was found between the two groups, though at other times of measurement, the differences were not significant.

Conclusions: Results showed that using Brimonidine 0.2% or Latanoprost 0.005% as prophylactic before YAG laser posterior capsulotomy could be effective in preventing IOP after treatment.


Brimonidine, Latanoprost, Xalatan, YAG laser capsulotomy

Full Text:



Rapuano CJ, Belin MW, Boxer Wachler BS, Donnenfeld ED, Feder RS, Rosenfeld SI, et al. Collagen shrinkage procedures. Refractive Surgery. Section 13. Singapore: American Academy of Ophthalmology (AAO); 2008:150-163.

Riordan-Eva P, FRCS, FRCO phth, Whitcher JP, Albiani DA. Vaughan and Asbury's General Ophthalmology 17th Edition; 2007:178-179.

Fechtner RD, Airaksinen PJ. Efficacy and tolerability of thedorzolamide 2%/ timolol 0.5% combination (COSOPTTM) versus latanoprost 0.005% (XALATANTM) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmologica Scand inavica. 2004;82:42-8.

Yeom HY, Lee JH, Hong YJ, Seong GJ. Brimonidine 0.2% Versus Brimonidine Purite 0.15%: Prophylactic Effect on IOP Elevation After Nd: YAG Laser Posterior Capsulotomy. Journal of Ocular Pharmacology and Therapeutics. 2006;22(3):176-81.

Chen TC. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. Journal of Cataract and Refractive Surgery. 2005;31:1707-12.

Yuen NSY, Cheung P, Hui SP. Comparing Brimonidine 0.2% to Apraclonidine 1.0% in the privention of intraocular pressure elevation and their pupillary effects following Laser peripheral Iridotomy. Japanese Ophthalmological Society. 2005;49:89-92.

Seong GJ, Lee JH, Lim SJ. Effect of 0.2% Brimonidine in preventing intraocular pressure elevation after Nd: YAG laser posterior capsulotomy. Ophthalmic Surg Laser. 2000;31(4):308-14.

Erdogan H, Toker MI, Arici MK, Topalkara A. Effect of latanoprost 0.005% and Brimonidine 0.2% on intraocular pressure after Phacoemulsification and intraocular Lens implantation surgery. Japanese Ophthalmological Society. 2004;48:598-601.

Novak-Laus K, Masnec-Paskvalin S. Use of antiglaucoma therapy to reduce acute intraocular pressure rise following neodymium: YAG laser iridotomy in angle-closure glaucoma patients. Acta Med Croatica. 2006;60(2):113-6.

Minello, Antonieta, Pereira A. Efficacy of topic ocular hipotensive agents after posterior capsulotomy. Arquivos Brasileiros de Oftalmologia 2008;71(5):706-10.

Nagar M, Ogunyomade A. A randomised prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89(11):1413-7.

Liu CJ, Ching-Yu C, Shu-Chiung C, Chiu AW, Chou JCK, Wen-Ming H, et al. Use of latanoprost to reduce acute intraocular pressure rise following neodymium: Yag laser iridotomy. Acta Ophthalmologica Scandinavia; 2002;282-286.

Gartaganis SP, Mela EK, Katsimpris JM. Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy. Ophthalmic Surg Lasers. 1999;30(8):647-52.

Stewart WC, Stewart JA. The Safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%. Acta Ophthalmologica Scand inavica. 2004;82:161-5.

Chevrier RL, Assalian A, Duperre J. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Ophthalmic Surg Lasers. 1999,Mar:30(3):199-204.

Unal M, Yucel I, Akar Y. Brinzolamid 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium: YAG laser posterior capsulotomy. Journal of Cataract and Refractive Surgery. 2006;32:1499-502.